Federal Grant Award Summary

Yale University received a $1.41 million Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded April 1, 2026, with a completion date of March 31, 2030. The grant supports fundamental research to identify and characterize the regulatory mechanisms governing ROS1 (Receptor Tyrosine Kinase), an unusual receptor protein implicated in fertility, cardiovascular disease, and cancer. The research will investigate how ROS1 receptors sense and transmit signals from their extracellular environment, examine how receptor mutations and cellular matrix changes affect ROS1 signaling in disease states, and explore the therapeutic potential of ROS1's unique structural elements as drug targets.

The funded research involves comprehensive biochemical and structural analysis of ligand-receptor complexes to elucidate the molecular mechanisms underlying ROS1 activation. By advancing understanding of this atypical receptor family's signaling pathways, the project aims to provide critical insights necessary for developing ROS1-specific inhibitors and clinical strategies to address ROS1-related diseases and mutations. Research will be conducted at Yale University's facilities in Connecticut over the four-year project period.